Shares of PharMerica Co. (NYSE:PMC) have received an average recommendation of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $29.25.

PMC has been the topic of a number of research analyst reports. Zacks Investment Research cut shares of PharMerica from a “buy” rating to a “hold” rating in a report on Tuesday, September 26th. ValuEngine raised shares of PharMerica from a “hold” rating to a “buy” rating in a report on Tuesday, October 31st.

In related news, CEO Gregory S. Weishar sold 521,089 shares of the company’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $29.25, for a total value of $15,241,853.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 534,089 shares of company stock worth $15,243,073. 5.04% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. California Public Employees Retirement System grew its stake in PharMerica by 5.6% in the 3rd quarter. California Public Employees Retirement System now owns 97,587 shares of the company’s stock valued at $2,859,000 after buying an additional 5,187 shares during the last quarter. Allianz Asset Management GmbH grew its stake in PharMerica by 3,347.4% in the 3rd quarter. Allianz Asset Management GmbH now owns 399,591 shares of the company’s stock valued at $11,708,000 after buying an additional 388,000 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in PharMerica by 1.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 269,518 shares of the company’s stock valued at $7,897,000 after buying an additional 3,864 shares during the last quarter. WINTON GROUP Ltd acquired a new position in shares of PharMerica during the 3rd quarter worth approximately $2,150,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of PharMerica during the 3rd quarter worth approximately $7,031,000. Institutional investors and hedge funds own 89.97% of the company’s stock.

Shares of PharMerica (NYSE:PMC) opened at $29.25 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.58 and a debt-to-equity ratio of 0.79. The stock has a market cap of $910.27, a PE ratio of 47.95, a PEG ratio of 1.27 and a beta of 0.82. PharMerica has a fifty-two week low of $22.00 and a fifty-two week high of $29.50.

PharMerica (NYSE:PMC) last issued its earnings results on Thursday, November 9th. The company reported $0.46 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.49 by ($0.03). The firm had revenue of $595.10 million during the quarter, compared to the consensus estimate of $596.80 million. PharMerica had a net margin of 0.54% and a return on equity of 2.30%. analysts predict that PharMerica will post 1.92 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/31/pharmerica-co-pmc-given-average-rating-of-hold-by-brokerages.html.

PharMerica Company Profile

Receive News & Ratings for PharMerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica and related companies with MarketBeat.com's FREE daily email newsletter.